The Gates Foundation will invest up to $50 million to support Tessera's SCD gene editing treatment, the company said.

More than 500,000 babies were tested for sickle cell disease in Catalonia’s newborn screening program, with 160 cases ...

The following is a summary of “Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 ...

There are many types of sickle cell disease. The majority of cases are divided into three subtypes depending on which genes you inherited: Hemoglobin is an iron-containing protein found in your ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

The new gene therapies for sickle cell disease—including the gene-editing ... that raises fetal hemoglobin levels. The FDA approved it in 1998. But Orkin says hydroxyurea and other available ...

The new gene therapies for sickle cell disease—including the gene-editing treatment Casgevy, based on research at Boston Children's Hospital—have been game-changing for the patients who have ...

Pociredir is under clinical development by Fulcrum Therapeutics and currently in Phase I for Sickle Cell Disease.

“Sickle cell disease (SCD) has a broad spectrum of ... instructions for his red blood cells to make a fetal form of hemoglobin. (Unlike “adult” hemoglobin, fetal hemoglobin doesn’t cause ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

In sickle cell disease, a gene mutation causes the hemoglobin molecules in red blood cells to form a rigid chain. This causes the cells to stiffen into a sickle shape, clogging blood vessels and ...